Inside the lawsuit that ended US gene patenting
By Heidi Ledford,
Nature
| 10. 25. 2021
Not so long ago, if you asked someone about the US Patent and Trademark Office’s practice of granting patents on human genes, you’d probably get one of two responses. Biotechnology insiders would shrug — such patents had been standard practice for decades. They were considered a linchpin of the burgeoning genetic-testing industry. Those less intimate with the inner workings of biotech often had a different reaction: “But that’s just … wrong,” said lawyer Chris Hansen. “Who can we sue?”
In 2009, Hansen, a veteran of civil-rights cases at the American Civil Liberties Union (ACLU) in New York City, embarked on a lawsuit that ended gene patenting in the United States. The effort seemed doomed, yet Hansen went on to win at the US Supreme Court, challenging the very idea of what patents are and what they should do.
The unexpected twists and turns of that case — as well as its impact on medicine, and particularly on the lives of women affected by breast and ovarian cancer — are ably and affectingly detailed in The Genome Defense. Its author...
Related Articles
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...